# Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection

> **NCT01129453** · PHASE1 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 51 (actual)

## Conditions studied

- Salmonella

## Interventions

- **BIOLOGICAL:** CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01129453
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-12
- **Final completion:** 2013-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2021-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01129453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01129453, "Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01129453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*